Gablofen may be a muscle agent and an antispastic agent.

Gablofen is employed to treat severe fitfulness; a movement disorder usually brought on by disseminated multiple sclerosis, brain disease, neural structure injury, brain trauma and stroke.

Gablofen can also be used for alternative functions unlisted during this medication guide.

Submit your review
1
2
3
4
5
Submit
     
Cancel

Create your own review

Average rating:  
 0 reviews
  • Gablofen
  • Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Call your doctor at once if you have any of these serious side effects:

    seizure (convulsions);
    confusion, hallucinations; or
    an uneven heartbeat.
    Less serious side effects may include:

    drowsiness, dizziness, weakness, tired feeling;
    agitation;
    low blood pressure;
    headache;
    confusion;
    sleep problems (insomnia);
    nausea, constipation; or
    increased urinary frequency or urinary retention.
  • Post-Implant Dose Titration Period To determine the initial total daily dose of GABLOFEN following implant, the screening dose that gave a positive effect should be doubled and administered over a 24-hour period, unless the efficacy of the bolus dose was maintained for more than 8 hours, in which case the starting daily dose should be the screening dose delivered over a 24-hour period. No dose increases should be given in the first 24 hours (i.e., until the steady state is achieved). In most patients, it will be necessary to increase the dose gradually over time to maintain effectiveness; a sudden requirement for substantial dose escalation typically indicates a catheter complication (i.e., catheter kink or dislodgement). Adult Patients with Spasticity of Spinal Cord Origin After the first 24 hours, for adult patients, the daily dosage should be increased slowly by 10% to 30% increments and only once every 24 hours, until the desired clinical effect is achieved. Adult Patients with Spasticity of Cerebral Origin After the first 24 hours, the daily dose should be increased slowly by 5% to 15% only once every 24 hours, until the desired clinical effect is achieved. Pediatric Patients After the first 24 hours, the daily dose should be increased slowly by 5% to 15% only once every 24 hours, until the desired clinical effect is achieved. If there is not a substantive clinical response to increases in the daily dose, check for proper pump function and catheter patency. Patients must be monitored closely in a fully equipped and staffed environment during the screening phase and dose-titration period immediately following implant. Resuscitative equipment should be immediately available for use in case of life-threatening or intolerable side effects.